[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"subjective-memory-complaint\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:subjective-memory-complaint":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100597879","validation-of-a-digital-intervention-to-rehabilitate-cognitive-resources-100597879",false,"NCT07064226","Validation of a Digital Intervention to Rehabilitate Cognitive Resources","Transcultural and Multidimensional Validation of dIgital Rehabilitation Intervention of COgnitive Resources Domain-Oriented - Work Package 4","MI-RICORDO","Inclusion Criteria:\n\n1. Montreal Cognitive Assessment (MoCA) score \\> 17.79;\n2. Clinical Dementia Rating (CDR) Scale score ≤ 1;\n3. Education level \\> 3 years;\n4. Age ≥ 65 years;\n5. Informed consent to participate, confirmed by signing the consent form;\n6. Availability of a caregiver\u002Fstudy partner able to support the participant;\n7. Stable pharmacological treatment (past 3 months) with acetylcholinesterase inhibitors, if applicable.\n\nExclusion criteria:\n\n1. Presence of dysmetria or marked auditory\u002Fvisual or communication disorders preventing the participation to the trial;\n2. Presence of ongoing rehabilitation program at the time of enrollment or in the 3 months prior to enrollment;","ALL","65 Years",{"count":20,"type":21},102,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to learn if the use of a digital cognitive rehabilitation system named RICORDO, that is flexible and capable of adapting the rehabilitation pathway according to the needs and capacity of the patients will prove effective for subjects with Subjective Memory Complaint or with Mild Cognitive Impairment or with Mild Dementia.\n\nThe main questions it aims to answer are:\n\nWill the RICORDO rehabilitation treatment, lead to an improvement in the global cognitive level? Will the RICORDO rehabilitation treatment lead to improved activation of participants in managing their own health and healthcare? Researchers will compare the multidomain cognitive rehabilitation strategy of RICORDO digital solution, with a standard paper pencil rehabilitation care (usual care).\n\nParticipants will undergo a comprehensive neuropsychological evaluation immediately before, immediately after and six months after the completion of the rehabilitation program.\n\nBoth interventions, the experimental and the usual care, will last 5 weeks, with 3 weekly sessions of 45 minutes each and can be done autonomously by the patient at home.",[27,28,29],"Mild Cognitive Impairment (MCI)","Subjective Memory Complaint","Dementia Alzheimer Type",[31,32,33,34,35,36,37,38],"telerehabilitation","Alzheimer disease","cognitive decline","cognitive rehabilitation","Digital medicine","Dementia","Mild Cognitive Impairment","neuroimaging","RECRUITING","2026-02-12",{"date":42,"type":43},"2026-02-13","ACTUAL",{"date":45,"type":43},"2025-10-06",{"date":47,"type":21},"2027-09-30",{"name":49,"class":50},"Fondazione Don Carlo Gnocchi Onlus","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":4,"enrollmentInfo":61,"targetDuration":4,"studyType":63,"phases":4,"briefSummary":64,"conditions":65,"keywords":71,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":51},"100623863","the-signature-of-alzheimers-disease-in-subjective-cognitive-decline-100623863","NCT07402161","The Signature of Alzheimer's Disease in Subjective Cognitive Decline","Unraveling the SIGNature of ALzheimer's Disease: Integrating Multimodal Biomarkers Through Machine Learning","SIGN-AL","Inclusion Criteria:\n\n* Clinical diagnosis of SCD according to the SCD-I criteria;\n* Mini-Mental State Examination (MMSE) score greater than 24, adjusted for age and education level;\n* Normal functioning on the Activities of Daily Living (ADL) and Instrumental Activities of Daily Living (IADL) scales.\n\nExclusion Criteria:\n\n* History of head trauma;\n* Current neurological and\u002For systemic diseases;\n* Symptoms of psychosis, major depression, or substance use disorder.","18 Years",{"count":62,"type":21},250,"OBSERVATIONAL","This study focuses on improving early detection of Alzheimer's disease (AD) in patients with subjective cognitive decline (SCD), a preclinical stage of cognitive impairment, in the context of emerging disease-modifying therapies (DMTs). Current biomarkers, such as brain MRI, PET scans, and cerebrospinal fluid (CSF) markers, are highly accurate but costly, invasive, and not widely accessible.\n\nThe study aims to provide cost-effective, scalable tools for early identification of individuals at risk, enabling personalized assessment and timely DMT administration.\n\nObjectives:\n\n* Evaluate the accuracy of innovative, easily accessible biomarkers in predicting biologically confirmed AD.\n* Assess the predictive utility of previously studied methods for SCD patients.\n* Explore new approaches, including automated speech analysis, to identify cognitive decline.\n* Evaluate genetic contributions to AD risk.\n* Integrate data from these various modalities using machine learning to create a predictive model for AD in SCD patients.\n\nStudy Design:\n\nThis is a multicenter, longitudinal, low-intervention study conducted at IRCCS Policlinico San Donato, San Donato Milanese, Milan, Italy (UO1) and the Center for Research and Innovation in Dementia, Careggi Hospital, Florence, Italy (UO2). Eligible participants are adults with SCD, intact daily functioning, and Mini-Mental State Examination (MMSE) scores \\>24. Exclusion criteria include neurological or systemic diseases, major psychiatric disorders, substance use, or prior head injury.\n\nParticipants undergo:\n\n* Detailed medical and family history collection.\n* Comprehensive neuropsychological, personality, and independence in daily activities assessment\n* EEG recording in resting state.\n* Blood sampling for plasma biomarkers (Aβ42, Aβ40, p-tau181, p-tau217, t-tau, NfL, GFAP).\n* CSF biomarker analysis (Aβ42, Aβ40, p-tau, t-tau).\n* Genetic analysis of AD-related genes (PSEN1, PSEN2, APOE, TREM2, ABCA7, BDNF, HTT).\n* Speech recording and analysis using standardized tasks to extract features for automated evaluation.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.\n\nProcedures:\n\n* Neuropsychological evaluations occur at baseline and two-year follow-up.\n* Language recordings are conducted in controlled settings using standardized picture description tasks.\n* EEG is recorded using 21-channel systems.\n* Blood and CSF samples are collected, processed, and stored at -80°C for subsequent analysis at respective institutional laboratories.\n* Plasma biomarkers are analyzed with Simoa technology; CSF biomarkers are analyzed using chemiluminescent enzyme immunoassay (CLEIA).\n* Genetic analyses employ PCR, high-resolution melting analysis (HRMA), sequencing, and capillary electrophoresis as appropriate for specific genes or polymorphisms.\n\nThe study expects to create a machine learning-based predictive model combining biomarker, neuropsychological, EEG, speech, and genetic data to improve early detection and guide personalized patient care.",[66,67,68,69,28,70],"Subjective Cognitive Decline (SCD)","Subjective Cognitive Complaints (SCCs)","Subjective Cognitive Impairment","Subjective Cognitive Concerns","Subjective Memory Decline",[72,73,74,75,76,77],"Alzheimer","Neuropsychology","EEG","Machine Learning","Biomarkers","Speech","2026-02-03",{"date":80,"type":43},"2026-02-11",{"date":82,"type":43},"2025-10-01",{"date":84,"type":21},"2028-03-01",{"name":86,"class":50},"IRCCS Policlinico S. Donato"]